Skip to content
Search

Latest Stories

Sumit Nagal becomes only third Indian to win an Olympic singles match

Sumit Nagal becomes only third Indian to win an Olympic singles match

SUMIT NAGAL on Saturday (24) won India’s first Olympic singles match in 25 years. He also became only the third Indian to win a men's singles match when he edged past Uzbekistan’s Denis Istomin in a three-setter at the Tokyo Games. 

Nagal got the better of Istomin 6-4 6-7(6) 6-4 in two hours and 34 minutes on court 10 at the Ariake Tennis Centre to set up a second-round with world number two Daniil Medvedev.


Zeeshan Ali was the first Indian to win a singles match at the 1988 Seoul Games when he beat Victo Caballero from Paraguay.

After that, Leander Paes won the historic men's singles bronze at the 1996 Atlanta Games, beating Brazil's Fernando Meligeni.

Nagal, 23, wasn’t even born when Leander Paes won the bronze in Atlanta.

India's Somdev Devvarman and Vishnu Vardhan competed at the 2012 Games in London but did not manage to cross the first round hurdle.

Nagal, who did not come into the Games in his best form, had a break opportunity in the sixth game of the opening set but could not convert.

The Indian, though, did not squander the opportunity when Istomin was serving to stay in the set.

An early break pushed Nagal ahead 2-0 in the second set in which he raced to a 4-1 lead but perhaps nerves got the better of him when he was serving for the match, up 5-3, and dropped his serve. The experienced Istomin forced a decider by prevailing in the tie-breaker.

The final set was on serve till Nagal got the decisive break. 

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less